“…Univariate analysis of the whole cohort concluded that nine HLA allelotypes (DR1,4,7; B8,12,40; A1,A2,A11) were associated with reduced risk of sensitization while five allelotypes (B42,53; A10,19,36) were associated with elevated risk of sensitization. 13 Fuller and Fuller demonstrated that 79% of anti-HLA-Bw4 antibody-producing patients expressed either DRB1*01 or DRB1*03 and concluded that these alleles might confer a high risk for both humoral allosensitization and renal allograft failure in case of HLA-Bw4 incompatibility. 21 On the other hand, another study showed that the presence of DR1 in the recipient was correlated with low immune response.…”